Akers Biosciences

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company that engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.

Thorofare, New Jersey, April  08, 2020  (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed a second milestone, the successful expression of the three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M), that were selected for their vaccine candidate. The antigens have been expressed using the D-CryptTM platform at Premas Biotech, which utilizes its vectors and S cerevisiae strain. Premas is now moving forward with purification and post-expression processing, which we believe should lead to a scaling up of the antigens.

Akers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens

Thorofare, New Jersey, April  07, 2020  (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 766,667 shares of the Company’s common stock, at a purchase price of $6.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 9, 2020, subject to the satisfaction of customary closing conditions.

Akers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Akers Biosciences Inc (NASDAQ: AKER) shares gap-opened higher Monday and were trading with handsome gains.

Akers Biosciences Rallies As CEO Says Company 'One Step Closer' To Effective Coronavirus Vaccine Candidate

Thorofare, New Jersey, April  06, 2020  (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate.

Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19

Thorofare, New Jersey, March  24, 2020  (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has acquired a licensing agreement with Premas Biotech, under which Akers will in-license a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™, and partner with Premas to ultimately seek FDA approval. The current global crisis has created the potential for an expedited review process from the FDA, which has recently noted its willingness to fast-track human clinical trials for certain coronavirus candidates.

Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech

Thorofare, New Jersey, Jan.  17, 2020  (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it reached a settlement agreement to settle two shareholder derivative actions: Watts v. Gormally, et al., No. 2:18-15992 (D.N.J.) and Chan v. Gormally, et al., No. 2:19-cv-4989 (D.N.J.). As previously reported, on October 2, 2019, the plaintiffs filed a motion for preliminary approval of the settlement. On January 8, 2020, the court entered an order that, among other things, granted preliminary approval of the settlement, approved the form and content of the parties' proposed notice of the settlement, directed the Company to issue a press release containing the information in that notice by today, and scheduled a hearing on May 28, 2020 to consider final approval of the settlement. Accordingly, below are the contents of the court-approved notice of the proposed settlement.

Akers Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative Litigation

Thorofare, New Jersey, Dec.  11, 2019  (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, announced today that on December 10, 2019, it received notice from the Hearings Advisor of the Nasdaq Office of General Counsel that the Company successfully regained compliance with the minimum bid price requirements set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market and that the Company is in compliance with all other applicable listing standards. Therefore, the Company’s scheduled hearing before the Nasdaq Hearing Panel has been cancelled and the Company’s common stock will continue to be listed and trade on The Nasdaq Stock Market.

Akers BioSciences Regains Compliance with Nasdaq Listing Standards

Thorofare, New Jersey, Dec.  09, 2019  (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the closing of its previously announced public offering of 613,500 common units at a public offering price of $4.00 per unit and 1,376,500 pre-funded units at a public offering price of $3.9999 per pre-funded unit, raising gross proceeds of $7.96 million, before deducting placement agent’s fees and other estimated offering expenses payable by Akers, assuming none of the preferred stock warrants issued in this offering are exercised. Akers intends to use the net proceeds from the offering for working capital and other general corporate purposes, which may include funding the exploration of strategic alternatives.

Akers BioSciences, Inc. Announces Closing of Approximately $8 Million Public Offering

Thorofare, New Jersey, Dec.  06, 2019  (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Executive Chairman Christopher Schreiber will attend the “Hemp Industry Daily Forum” on Tuesday, December 10, 2019 as part of MJBizCon Week at the Las Vegas Convention Center in Las Vegas, Nevada. Akers Advisory Board member Bob Hoban is a featured speaker presenting on “International Opportunities” for Hemp operations within the Textiles to Cannabidiol (CBD) space.

Akers Biosciences to Attend Hemp Industry Daily Forum in Las Vegas, Nevada

Thorofare, New Jersey, Dec.  05, 2019  (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the pricing of a public offering of 1,990,000 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one preferred stock warrant to purchase one share of Series C Convertible Preferred Stock. The units are being offered at a public offering price of $4.00 per unit.

Akers BioSciences, Inc. Announces Pricing of Approximately $8 Million Public Offering

· Establishes Advisory Board appointing Bob Hoban and Michael Patterson

Akers Biosciences Continues Strategic Review; Explores Leveraging its 30-years of Laboratory Operations to Enter into the Hemp and Minor Cannabinoid Processing Industry

THOROFARE, N.J., Nov.  22, 2019  (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, today announced that effective at 8:00 a.m. eastern standard time on Monday, November 25, 2019, the Company will effect a reverse stock split of its issued and outstanding common stock of no par value at a ratio of one (1) share of common stock for every twenty four (24) shares of common stock. As a result of the reverse stock split, every twenty four of the Company’s issued and outstanding shares of common stock will be automatically converted into one share of common stock.

Akers Biosciences, Inc. Announces One-for-Twenty Four Reverse Stock Split

News for Akers Biosciences Stock (AKER)